Protein-bound β-1,4-glucan from Trametes versicolor
The $500M Mushroom Pharmaceutical
$500M+
Annual Sales (Peak)
1977
Approved Since
Dozens of RCTs
Clinical Trials
Multiple
Meta-Analyses
PSK (Polysaccharide-K, trade name Krestin) is the most commercially successful mushroom-derived pharmaceutical in history. Extracted from Turkey Tail mushroom (Trametes versicolor), PSK has been an approved and widely prescribed immunomodulatory agent in Japan since 1977. At its peak, it generated over $500 million in annual sales and was one of Japan's best-selling pharmaceutical products of any kind. PSK represents the gold standard of what mushroom science can achieve when traditional knowledge meets rigorous clinical development.
The development of PSK began in the 1960s when Japanese researchers at Kureha Chemical Industry Co. began systematically fractionating Turkey Tail extracts to identify the most immunologically active component. By 1971, they had isolated and characterized PSK — a protein-bound polysaccharide with a molecular weight of approximately 100 kDa. Clinical trials began immediately, and PSK was approved by Japan's Ministry of Health and Welfare in 1977. For over four decades, it has been prescribed alongside conventional protocols, making Turkey Tail arguably the most medically validated mushroom in modern pharmaceutical history.
Approved pharmaceutical in Japan since 1977
Extensive clinical trial data spanning 40+ years
Activates NK cells, cytotoxic T-cells, and macrophages
Supports immune surveillance and natural defense mechanisms
Demonstrated improvement in quality-of-life scores
Prebiotic effects supporting gut microbiome health
PSK Composition & Analogs
A protein-bound beta-glucan (~100 kDa) with a 1,4 backbone and 1,3/1,6 branches. The protein component (~38% by weight) enhances solubility and receptor binding.
The structural feature of PSK that binds to Toll-like Receptor 2 on macrophages and dendritic cells, initiating the innate immune cascade.
Independently isolated from Turkey Tail in China. Similar molecular weight and mechanism but different protein composition. Used clinically in China.
A subfraction that activates the complement system (C3a, C5a), enhancing opsonization and pathogen clearance.
PSK has been the subject of over 400 published studies, including dozens of randomized controlled trials and multiple meta-analyses. A 2007 meta-analysis in Cancer Immunology, Immunotherapy reviewed 8 RCTs comprising over 8,000 patients and concluded that PSK significantly improved survival markers when used as an immune adjuvant. Its mechanism involves binding to TLR-2 (Toll-like receptor 2) on immune cells, triggering NF-κB activation, cytokine production (IL-12, TNF-α), and enhanced NK cell and cytotoxic T-cell activity. PSP (Polysaccharopeptide), the Chinese equivalent isolated independently from Turkey Tail, has generated its own substantial body of clinical evidence with similar immunological mechanisms.
*These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before starting any supplement regimen.